, Ibrahim Aly, Essam H. Ibrahim, Rabab S. Hamad, et al
Abstract
Purpose Schistosomiasis is a disease that aficts over 220 million people worldwide. To date, there is no vaccine against
schistosomiasis and chemotherapy relies basically on a single drug, praziquantel. The current study was undertaken to investigate the therapeutic efects of monophosphoryl lipid A (MPLA) as an adjuvant in soluble egg antigen (SEA)-vaccinated
and Schistosoma mansoni-infected mice.
Methods Mice were divided into two groups of uninfected and Schistosoma mansoni infected. The two groups were treated
diferently with MPLA, SEA and praziquantel. Study parameters included parasitological, immunological and biochemical
parameters.
Results Parasitological parameters revealed that intraperitoneal injection of MPLA into SEA-vaccinated and S. mansoniinfected mice was efective in reducing the worm and egg burden, granuloma count and diameter as well as the total area
of infection in their livers versus SEA-untreated but infected ones. In addition, MPLA showed ameliorative action on the
elevated liver oxidative stress marker, including malondialdehyde (MDA) and a decrease in the level of the antioxidant
enzymes, reduced glutathione (GSH) and catalase (CAT) which may have a role in the liver damage and fbrosis due to S.
mansoni infection.
Conclusion Treatment with MPLA has multi-functions in attenuating the deleterious impacts of S. mansoni infection in
mice livers. Its efects are mediated through a reduction of ova count, worm burden, granuloma diameter and amelioration
of antioxidant defense systems, and liver function biomarkers
رباب سالم حمد | Rabab Salem Hamad | 10108